Citrulline (CIT) is a non-essential amino acid, which acts as a nitrogen ion acceptor 24 from carbamoyl-phosphate within the urea cycle. The dietary supplement citrulline 25 malate (CM) has been purported to improve aerobic and anaerobic exercise 26 performance via a variety of mechanisms including improved ammonia, arginine and 27 lactic acid metabolism, alongside an increase in ATP production (da Silva et al., 28 2018) . Increasing muscle CIT may attenuate ammonia accumulation resulting in a 29 lactic acid buffer effect, which might enhance subsequent recovery, attenuate fatigue 30 and reduce post exercise muscle soreness (Ochia et al., 2012; Cutufrello et al., 31 2015) . Ammonia influences fatigue by stimulating phosphofructokinase, leading to 32 an increased rate of glycolysis (Takeda et al., 2011) . This may increase blood lactic 33 acid during exercise inhibiting pyruvate oxidation leading to hydrogen ion 34 accumulation, and a reduction in muscle pH, and contractile potential (Cutufrello et 35 al., 2015) . 36
Citrulline is also adjacent to arginine succinate in the urea cycle, and can be directly 37 synthesised to arginine. Studies have demonstrated that supplementation with CIT 38 increases circulating levels of arginine, which may simultaneously acting as a lactic 39 acid buffer, and vasodilator via nitric oxide synthase (Takeda et al., 2011; Cutufrello 40 et al., 2015; Martinez-Sanchez et al., 2017) . Trials have demonstrated that blood 41 arginine increases to a greater extent with oral CIT than arginine due to splanchnic 42 extraction (Moinard et al., 2008; Sureda et al., 2010; Takeda et al., 2011; Wijnands et 43 al., 2015) . By way of comparison, a 0.75 g twice daily oral dose of CIT resulted in 44 similar increase in blood arginine compared to a 1.6 g twice daily dose of arginine 45 (Schwedhelm et al., 2007) . Finally, malate acid is combined with CIT to form the salt 46 CM. Malate is an intermediate in the TCA cycle, and increasing the pool size of 47 6 subjects performed the GVT barbell curl protocol (10 sets to failure with a maximum 96 of 10 repetitions per set, one-minute rest between sets). The total number of 97 repetitions was counted across each set, and failure was determined when a full 98 range of motion could no longer be completed. Following the GVT a second blood 99 sample was taken, subjects then completed the muscle soreness VAS and then 100 again at 24, 48 and 72 h. The following week subjects completed the trial under the 101 opposite treatment condition. 102 103
Anthropometrics and Muscle Soreness Scale 104
Height and weight were assessed using a stadiometer (Holtain, Crymych, United 105 Kingdom) and column scale (Seca, Birmingham, United Kingdom), body composition 106 via bioelectrical impedance (Bodystat 1500, Douglas, Isle of Man) and body mass 107 index (BMI) was calculated kg/m 2 . Muscle soreness was scored using a 100 mm 108 VAS at four sites on the upper and lower arm (Biceps brachii: long and short head 109 and Brachioradialis and Flexor carpi radialis). On the VAS 0 indicated no pain, and 110 100 indicated the worst pain imaginable. The sum of the four sites was combined and 111 used to represent total soreness at each time point. Muscle soreness was recorded 112 immediately pre and post exercise under supervision and self-assessed at 24, 48 113 and 72 h following GVT. A demonstration of how to self-palpate and score the 114 muscle soreness was provided by the researchers along with an instruction sheet 115 with diagrams detailing the points of palpation. The research team reminded the 116 subjects to complete muscle soreness VAS at the same time of day using both text 117 message and email prompts. 118
119

Supplementation Protocol 120
Subjects were provided with either 8 g of CM (1.1:1 ratio, 4.2 g citrulline, 3.8 g malate, 121
Bulk Powders, United Kingdom), or a placebo 6 g of citric acid (Sigma-Aldrich, Dorset, 122 United Kingdom). Both placebo and supplement drinks were mixed in 70 ml of fruit 123 cordial and 150 ml of water and consumed within 5 minutes. The dosages and timing 124 of the CM were based on research showing that peak CIT levels occur 1 h after 125 administration (Moinard et al., 2008) . The CM and placebo drinks were both well 126 tolerated, and subjects reported no side effects. 127
128
Assessment of Supplement Quality 129
Determination of the supplement quality was assessed using nuclear magnetic 130 resonance (NMR) spectroscopy. The CM utilised in the present investigation had a 131 purported ratio of 2:1 citrulline to malate (Bulk Powders, United Kingdom). Briefly, a 132 standard NMR tube containing 100 mg of the CM supplement powder was added to 133 1 mL of D 2 O (Fisher Scientific, UK). The sample was then warmed to 40 °C and 134 agitated to ensure complete dissolution of the solid for analysis of the total organic 135 fraction. Once the solid was dissolved, the solution was cooled to room temperature 136 and analysed on a Bruker Avance DPX-400 NMR spectrometer operating at 137 resonance frequencies of 400 MHz (1H) and 100 MHz used to analyse the data (see Table 2 ). Nutrition data was adjusted for bodyweight 181 and expressed as grams and calories per kg of bodyweight. 182
183
Statistics 184
All data were analyzed using SPSS (IBM, version 24). The main outcome measure, 185 RT performance during GVT, was analysed using a 2 condition (CM and placebo) 186 repeated measures analysis of variance to determine any differences in performance 187 over the ten sets (treatment × time). Treatment order was added to the model as a 188 covariant (treatment × time × order). Muscle soreness was analysed in the same way, 189 using the sum of the 4-site muscle soreness VAS for each time point. intake, between CM and placebo conditions (Table 2) . Subjects confirmed that they 203 did not stop or start any new supplements over the duration of the trial. Determination 204 of the citrulline to malate ratio revealed the supplement contained a 1.1:1 ratio 205 citrulline to malate rather than the purported 2:1 ratio advertised on the back of the 206 packaging. Resistance training performance during the GVT is presented in Figure 1 . 207
There was no significant difference, between the CM and placebo condition, on GVT 208 performance, measured by repetitions performed per set (treatment × time p = 0.174). 209
Treatment order had no effect on GVT performance (treatment × time × order p = 210 0.217). There was a significant effect of time (p < 0.001) on GVT performance, e.g. 211 the number of repetitions performed declined as sets progressed (mean repetitions 212 set 1, placebo 9.8 ± 0.7 vs CM 9.5 ± 1.1; set 10, placebo 4.4 ± 2.9 vs CM 4.6 ± 2.4). Blood lactate data is presented in Figure 2 . Lactate increased significantly (p < 0.001) 218 post GVT in both the CM (mean lactate pre, 1.9 ± 0.6, post 4.7 ± 2.0 mM) and 219 placebo conditions (mean lactate pre, 1.8 ± 0.6, post 4.9 ± 1.7 mM). There was 220 In the current investigation, we hypothesised that an acute dose of CM prior to an 237 exercise session would increase the total amount of work performed during GVT. 238
Citrulline malate had no effect on GVT performance, blood lactate or CK compared to 239 a placebo, although subjects did report an overall reduction in muscle soreness. The 240 results of the present investigation accept the null hypothesis and are in agreement 241 with recent findings showing no effect of CM on RT performance (Farney et al., 2017; 242 Chappell et al. 2018; da Silva et al., 2018,) . Moreover, these findings are in contrast 243 to others who have identified an effect of CM with RT (Wax et al., 2015; Wax et al., 244 2016; Glenn et al., 2017) . Specifically, Perez-Guisda and Jakeman (2010) The reduction in soreness identified with CM was accompanied by a lack of 251 difference in the total amount of work performed between treatment groups. This 252 could lead to the conclusion that less soreness was elicited from the same workload 253 when the subjects consumed CM. Although we note that subjects did not report high 254 values for muscle soreness pre or post exercise, which may reflect the nature of the 255 exercise i.e only small muscle groups were involved in our protocol. da Silva et al. 256 2017 and , both found a greater degree of soreness, this seems 257 to be commensurate with protocols involving larger muscle groups. We also note a 258 lack of any immediate difference in CK or lactate levels between conditions, which 259 might be expected to accompany any difference in soreness. The lack of change, in 260 these markers or muscle damage and exercise intensity is in agreement with recent 261 13 trials utilising CM during RT protocols (Wax et al., 2015; Wax et al., 2016; da Silva et 262 al., 2017; Farney et al., 2017) . Effects of CM on muscle soreness and RT have so far 263 produced mixed results, with both reductions in soreness (Perez-Guisado & Jakeman 264 2010) and no difference when compared to placebo (da Silva et al., 2017; Chappell 265 et al., 2018) . Curiously, trials of aerobic exercise have so far indicated a reduction in 266 soreness utilising CM (Tarozona-Diaz et al., 2013 , Martinez-Sanchez et al., 2017 . 267
Potential explanations for a reduction in soreness therefore may be attributed to 268
CIT's role in the urea cycle and the augmented clearance of ammonia (Callis et al., 269 1991) . 270
Finally, we sought to corroborate the level of the active ingredient used in the present 271 investigation with the manufacturer's labelling. The data suggests that the amounts of 272 active ingredient in the supplement varied, by almost half, from the manufacturers 273 labelling. The dosage consumed by subjects was 4.2 g CIT and 3.8 g malate (1.1:1 274 ratio) instead of the intended 6 g CIT and 2 g malate (2:1 ratio). A previous 275 investigation reported similar findings from five "over the counter" CM supplements 276 .The disparity between the actual and intended dosage may 277 account for a lack of significant findings. Moinard et al., (2008) however, reported a 278 significant increase in plasma CIT using a similar dosage to the one used in the 279 present investigation. Moreover, the data highlights the need for researchers to 280 conduct analyses of supplement quality prior to publishing trials. Caution therefore 281 needs to be taken when assessing any dose-response study using commercial CM 282 supplements. Commercial supplements, however, are the products recreationally 283 active individuals and athletes alike use in an attempt to aid recovery and improve 284 performance. 285
286
Strengths and Limitations 287
A counterbalanced design was employed to account for a potential training effect, 288 and statistical analysis identified that subjects did not perform better on their second 289 GVT session compared to the first. There was also no difference in dietary intake for 290 the 24 hours preceding testing, between the CM and placebo conditions, Therefore 291 any lack of statistical finding may not be attributed to a disparity in diet (e.g. an 292
increased carbohydrate or energy intake between conditions). 293
The investigation did not include a measure of ammonia to accompany the data 294 gathered on lactate and CK to corroborate the difference in muscle soreness. 295
Furthermore, although we advised subjects to rest 48 h prior to commencing the trial, 296 several subjects had elevated CK suggesting engagement in prior exercise. 297
Increases in CK levels in response to exercise are known to be highly variable and 298 increase significantly in days following exercise (Ehlers et al. 2002) . Creatine kinase 299 was only measured immediately post exercise and a measurement taken alongside 300 muscle soreness over 72 h would have elucidated the recovery process more clearly. 301
Moreover, measurements of muscle soreness were self-reported between the 24-72 302 h measures potentially and supervised measures would have been preferable. The 303 subjects involved in the present investigation were not a homogenous group. 304
Training experience varied and no controls were put in place to account for the 305 impact of menstrual cycling. Finally, we utilised citric acid as a placebo condition. We 306 only found a single study focused on the effect of citric acid on exercise. Sugino et al. 307 (2007) utilised an 8 day loading protocol combined with aerobic exercise, the authors 308 found no effect on performance, blood citric acid or lactate levels. The placebo was 309 effective at replicate the taste of CM and was well tolerated. 310 15 Subjects completed the trial fasted to eliminate the influence of feeding on 311
performance. We could alternatively have included a standardised breakfast in the 312 protocol to reflect the probability that exercise is often not carried out in a fasted state. 313
Finally, we asked the participants not to stop or start any other supplement intake for 314 the duration of the trial and a condition of participation was that they weren't taking 315 any supplements containing CM. Although we acknowledge the potential effects of 316 other supplements on performance the crossover design of this study to some extent 317 mitigates against this. Secondly we are reminded of the real-world nature of 318 supplement intake whereby in reality people will not postpone ongoing 319 supplementation regimes when they begin new ones. 320
321
Conclusion 322
An acute dose of 8 g CM (1.1:1 ratio) did not confer any benefits to the main outcome 323 measure of RT performance, in a moderately trained group. Total muscle soreness 324 was reduced over the 72 h following CM treatment however; both CK and lactate 325 were unaffected immediately following exercise. This is the first study to date to test 326 the effectiveness of CM using a GVT free weight exercise protocol. Tables   Table 1 Participant Characteristics (n -19, 12 25.7 ± 7.7 1.7 ± 0.1 75.3 ± 13.7 24.8 ± 2.9 18.3 ± 5.8
Abbreviations: m, metres; kg, kilogram; BMI, body mass index.
All values are mean ± SD 23 
